Abstract
Primary biliary cholangitis (PBC) is a chronic autoimmune disease causing inflammation in interlobular bile ducts, leading to cholestasis, hepatocyte damage, and fibrosis. Often asymptomatic at diagnosis, common symptoms include fatigue and pruritus, impacting patients' quality of life. Diagnosis relies on elevated liver biochemistries in a cholestatic pattern with detectable antibodies. Ursodeoxycholic acid (UDCA) effectively treats PBC in two-thirds of patients, with obeticholic acid (OCA) as an additional option for non-responders. Ongoing research explores new drugs for UDCA inadequate-responders. Liver transplantation (LT) is successful for synthetic dysfunction or decompensated disease, but recurrence occurs in up to 40% of cases. Emerging therapies offer hope for improved management of PBC.